Nonalcoholic Fatty Liver Disease: Current Global Burden

Semin Liver Dis. 2022 Aug;42(3):401-412. doi: 10.1055/a-1862-9088. Epub 2022 May 26.

Abstract

The map and global disease burden of chronic liver diseases are markedly changing, with nonalcoholic fatty liver disease (NAFLD) becoming the most common cause of liver diseases coinciding with the current epidemics of obesity, type 2 diabetes, and metabolic syndrome. Understanding the incidence and prevalence of NAFLD is critical because of its linkage to a significant economic burden of hospitalization and changing patterns in consequences, such as liver transplantation. Moreover, the long-term average health care expenses of NAFLD patients have exceeded those of other liver diseases. To lessen the imminent burden of NAFLD, immediate actions to raise worldwide awareness and address metabolic risk factors are required. This review summarizes key data about the global disease burden of NAFLD, modifiable and nonmodifiable risk factors, and current preventive approaches.

Publication types

  • Review

MeSH terms

  • Diabetes Mellitus, Type 2*
  • Humans
  • Incidence
  • Liver Transplantation*
  • Non-alcoholic Fatty Liver Disease* / epidemiology
  • Non-alcoholic Fatty Liver Disease* / therapy
  • Prevalence